Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce and release growth hormone. The 'no DAC' version (Modified GRF 1-29) has a shorter half-life and produces more natural, pulsatile GH release. It is one of the most commonly used peptides in anti-aging and body composition protocols, typically stacked with Ipamorelin.
Mechanism of action
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and secretion. The modified amino acid sequence (four substitutions) protects against enzymatic degradation by DPP-IV, extending its biological activity. It amplifies the natural GH pulse rather than creating a constant elevation, preserving the physiological pulsatile pattern.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| GH release / body composition | subcutaneous | 100–300 mcg | 2-3x daily | Best combined with Ipamorelin at same injection. Inject on empty stomach. 8-12 week cycles. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Clinical studies demonstrate 2-10x increases in GH and IGF-1 levels. A key 2006 study showed CJC-1295 with DAC increased mean GH levels by 46% and IGF-1 by 45% after a single injection, with effects lasting 6-8 days. The no-DAC version produces shorter, more physiological GH pulses. Generally well-tolerated with side effects limited to injection site reactions, flushing, and headache.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with CJC-1295 for synergistic effects.
Legal status
Under FDA reclassification review as part of the 14-peptide RFK Jr. initiative. Previously available from research peptide suppliers.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.